SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Avista Public Acquisition Corp. II (Nasdaq – AHPA)

BALA CYNWYD – March 24, 2022 /Globe Newswire/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Avista Public Acquisition Corp. II (“Avista II” or the “Company”) (Nasdaq – AHPA) for possible breaches of fiduciary duty and other violations of federal and state law in connection with an agreement pursuant to which Avista II, a special purpose acquisition company, will combine with OmniAb (“OmniAb”), Ligand Pharmaceuticals Incorporated’s antibody discovery platform which provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics, and result in OmniAb becoming a publicly traded company. Under the terms of the agreement, Avista II shareholders will retain ownership of approximately 20.3% of the combined company.

The investigation concerns whether the Avista II Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution of ownership interest in the combined company.

If you own shares of Avista II stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, Two Bala Plaza, Suite 805, Bala Cynwyd, PA 19004, or call toll free 855-576-4847.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.